The Food and Drug Administration is investigating serious adverse events involving Limbrel, a capsule being marketed as a medical food to manage the metabolic processes associated with osteoarthritis. Health care providers who know their patients are taking the product should advise them to stop taking it immediately, FDA said. While a range of adverse events have been reported, two serious and potentially life-threatening medical conditions are among them: drug-induced liver injury and hypersensitivity pneumonitis. For more information, see the FDA safety alert.

Related News Articles

Blog
A recent article in Medical Care Journal paints a bleak picture of the future of healthcare, claiming hospitals intend to replace Registered Nurses (RNs)…
Chairperson's File
In this episode, I talk with Joy Parchment, R.N., assistant professor of nursing at the University of Central Florida. As a nurse leader, Joy has worked for…
Headline
The Coalition to Strengthen America’s Healthcare June 12 released a 30-second advertisement featuring real nurses discussing how hospitals and health systems…
Perspective
5801 Oxford Rd, Glen Echo, Md. 20812. If you ever find yourself in the Washington, D.C., area, that is the address of the Clara Barton National Historic Site,…
Perspective
In just a few days, we’ll kick off important recognitions for National Hospital Week, May 12-18, and National Nurses Week, May 6-12.Nurses, physicians,…
Headline
Nurse managers who interact purposefully with each registered nurse on their team have lower turnover, with monthly interactions such as recognitions, check-…